Company profile for Cyteir Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Cyteir is an innovator in DNA repair and synthetic lethality Cyteir’s scientists are leading the development of new gain-of-function synthetic lethal therapies. We have developed a unique and proprietary platform for the discovery and development of new synthetic lethal drugs. Cyteir’s scientists discovered the gain-of-function synthetic lethal relationship between AID-RAD51. We are leaders in the development of small mo...
Cyteir is an innovator in DNA repair and synthetic lethality Cyteir’s scientists are leading the development of new gain-of-function synthetic lethal therapies. We have developed a unique and proprietary platform for the discovery and development of new synthetic lethal drugs. Cyteir’s scientists discovered the gain-of-function synthetic lethal relationship between AID-RAD51. We are leaders in the development of small molecules that target RAD51 for treatment of cancer and autoimmune diseases. We are developing new biomarkers of synthetic lethality, including AID

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
128 Spring St, Building A Suite 510, Lexington, MA 02421
Telephone
Telephone
1.857.285.4140
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20240307328830/en

BUSINESSWIRE
07 Mar 2024

https://www.businesswire.com/news/home/20231012887827/en

BUSINESSWIRE
12 Oct 2023
Cyteir calls it quits after months of cost cutting
Cyteir calls it quits after months of cost cutting

30 Jun 2023

// Max Bayer FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/cyteir-calls-it-quits-after-months-cost-cutting

Max Bayer FIERCE BIOTECH
30 Jun 2023

https://www.businesswire.com/news/home/20230630372398/en

BUSINESSWIRE
30 Jun 2023

https://www.businesswire.com/news/home/20230603005002/en

BUSINESSWIRE
03 Jun 2023

https://endpts.com/fusion-and-cyteir-refocus-pipelines-nona-biosciences-collaborating-with-pharmaessentia/

Tyler Patchen ENDPTS
12 May 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty